Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Abstract: A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and therefore the monooxygenase in the present invention has a good industrial application prospect in the production of proton pump inhibitors for the treatment of gastric ulcers.

Abstract: A monooxygenase having an amino acid sequence obtained by mutation of the amino acid sequence shown in SEQ ID NO:2 is disclosed. The use of the monooxygenase of the present invention in production of chiral sulfoxide-based drugs has advantages including mild reaction conditions, environmental friendliness, high yield, high optical purity of products, less peroxide products, and the like, and therefore the monooxygenase in the present invention has a good industrial application prospect in the production of proton pump inhibitors for the treatment of gastric ulcers.

Abstract: A high performance liquid chromatography method used for dexrazoxane-related substances is provided, and in the method, a low-density bonding reversed-phase C18 chromatographic column resistant to pure water is employed; a gradient elution is carried out with mobile phase A and mobile phase B as eluents, the mobile phase A being a buffer, and the mobile phase B being an organic solvent; the volume percent of mobile phase A in eluents in a first stage of the gradient elution is not lower than 90%, and the duration of the first stage of the gradient elution ranges from 15˜30 minutes. By means of the analytical method, dexrazoxane is effectively separated from main impurities, and the qualities of the active pharmaceutical ingredients of dexrazoxane and the preparations thereof could be better controlled.

Abstract: A dexrabeprazole sodium compound includes crystal forms B and C. The crystal form B has good stability and flowability. The crystal form C is an anhydrous crystal form and has good stability and low hygroscopicity. The crystal forms are suitable for preparing a dexrabeprazole sodium preparation.

Abstract: A strain of Burkholderia is Burkholderia glathei ECU0712, with an accession number of CGMCC NO. 14464. With the strain or its extract as the biocatalyst, thioether is catalyzed to be oxidized asymmetrically to chiral sulfoxide, with significant advantages that the obtained product has a high optical purity, and benefits of a simple reaction system, short preparation time of the catalyst and a high yield of the product.

Abstract: An injectable pharmaceutical composition of a sulfonylurea drug and a preparation method thereof were described. The pharmaceutical composition contains a sulfonylurea drug, a cyclodextrin and an additive.

Abstract: A strain of Burkholderia is Burkholderiaglathei ECU0712, with an accession number of CGMCC NO. 14464. With the strain or its extract as the biocatalyst, thioether is catalyzed to be oxidized asymmetrically to chiral sulfoxide, with significant advantages that the obtained product has a high optical purity, and benefits of a simple reaction system, short preparation time of the catalyst and a high yield of the product.

Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.

Abstract: A method for preparing a ?-nucleoside compound, including the following steps: 1) performing a silylation reaction of a nitrogenous base or an analogue thereof in the presence of TMSOTf to give the nitrogenous base or the analogue thereof being protected by trimethylsilyl; 2) performing a direct glycosylation reaction of the reaction liquid, without being isolated, and a five- or six-membered ring saccharide or a derivative thereof closed by a hydroxyl protecting group to give a closed ?-nucleoside compound; and 3) performing a deprotection reaction to give the ?-nucleoside compound. The method uses a one-pot process to prepare the key intermediates of the ?-nucleoside compound, and the yield of materials in ?-configuration increases significantly. The method has the benefits of simple operations, being energy conservation and environment protection, and being suitable for industrial applications.

Abstract: A dexrabeprazole sodium compound includes crystal forms B and C. The crystal form B has good stability and flowability. The crystal form C is an anhydrous crystal form and has good stability and low hygroscopicity. The crystal forms are suitable for preparing a dexrabeprazole sodium preparation.

Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.

Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Abstract: A high performance liquid chromatography method used for dexrazoxane-related substances is provided, and in the method, a low-density bonding reversed-phase C18 chromatographic column resistant to pure water is employed; a gradient elution is carried out with mobile phase A and mobile phase B as eluents, the mobile phase A being a buffer, and the mobile phase B being an organic solvent; the volume percent of mobile phase A in eluents in a first stage of the gradient elution is not lower than 90%, and the duration of the first stage of the gradient elution ranges from 15˜30 minutes. By means of the analytical method, dexrazoxane is effectively separated from main impurities, and the qualities of the active pharmaceutical ingredients of dexrazoxane and the preparations thereof could be better controlled.

Abstract: A method for preparing a ?-nucleoside compound, including the following steps: 1) performing a silylation reaction of a nitrogenous base or an analogue thereof in the presence of TMSOTf to give the nitrogenous base or the analogue thereof being protected by trimethylsilyl; 2) performing a direct glycosylation reaction of the reaction liquid, without being isolated, and a five- or six-membered ring saccharide or a derivative thereof closed by a hydroxyl protecting group to give a closed ?-nucleoside compound; and 3) performing a deprotection reaction to give the ?-nucleoside compound. The method uses a one-pot process to prepare the key intermediates of the ?-nucleoside compound, and the yield of materials in ?-configuration increases significantly. The method has the benefits of simple operations, being energy conservation and environment protection, and being suitable for industrial applications.